Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?

Gao FF, Krasinskas AM, Chivukula M.

Appl Immunohistochem Mol Morphol. 2012 May;20(3):272-6. doi: 10.1097/PAI.0b013e3182366531.

PMID:
22498671
2.

Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.

Ordóñez NG.

Mod Pathol. 2013 Apr;26(4):553-62. doi: 10.1038/modpathol.2012.200. Epub 2012 Nov 30.

3.
4.

PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.

Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS.

Am J Surg Pathol. 2010 May;34(5):627-35. doi: 10.1097/PAS.0b013e3181da7687.

PMID:
20414098
6.

Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.

Kawai T, Tominaga S, Hiroi S, Ogata S, Nakanishi K, Kawahara K, Sonobe H, Hiroshima K.

J Clin Pathol. 2016 Aug;69(8):706-12. doi: 10.1136/jclinpath-2015-203211. Epub 2016 Jan 4.

PMID:
26729015
7.

Melan A (A103) is not a marker of mesothelioma.

Ordóñez NG, Shen SS, Zenali M, Deavers MT.

Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):181-4. doi: 10.1097/PAI.0b013e31825e0013.

PMID:
22820661
9.

PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.

Brenne K, Nymoen DA, Reich R, Davidson B.

Am J Clin Pathol. 2012 Feb;137(2):240-7. doi: 10.1309/AJCPGA95KVSAUDMF.

PMID:
22261449
10.
11.
12.

Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.

Andrici J, Jung J, Sheen A, D'Urso L, Sioson L, Pickett J, Parkhill TR, Verdonk B, Wardell KL, Singh A, Clarkson A, Watson N, Toon CW, Gill AJ.

Hum Pathol. 2016 May;51:9-15. doi: 10.1016/j.humpath.2015.12.012. Epub 2015 Dec 29.

PMID:
27067777
13.
14.

PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.

Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK.

Mod Pathol. 2009 Sep;22(9):1243-50. doi: 10.1038/modpathol.2009.92. Epub 2009 Jun 12.

15.

High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression.

Roh MH, Yassin Y, Miron A, Mehra KK, Mehrad M, Monte NM, Mutter GL, Nucci MR, Ning G, Mckeon FD, Hirsch MS, Wa X, Crum CP.

Mod Pathol. 2010 Oct;23(10):1316-24. doi: 10.1038/modpathol.2010.119. Epub 2010 Jun 18.

16.

Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.

Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B.

Virchows Arch. 2012 Feb;460(2):193-202. doi: 10.1007/s00428-011-1191-x. Epub 2012 Jan 17.

PMID:
22249560
18.

The diagnostic challenge of peritoneal mesothelioma.

Krasuski P, Poniecka A, Gal E.

Arch Gynecol Obstet. 2002 Jul;266(3):130-2.

PMID:
12197549
19.

From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation.

Levy AD, Arnáiz J, Shaw JC, Sobin LH.

Radiographics. 2008 Mar-Apr;28(2):583-607; quiz 621-2. doi: 10.1148/rg.282075175. Review.

PMID:
18349460

Supplemental Content

Support Center